Uncover the potential of nivolumab and axicabtagene ciloleucel as they showcase promising results in the latest lymphoma trials, potentially reshaping the standard of care for these malignancies.

Innovations in mRCC management are accelerating, and significant shifts have already begun with the ODYSSEY RCC study and the first-ever comprehensive ASCO guidelines for metastatic clear-cell RCC – read on to stay ahead of the curve.

Explore the multidisciplinary approach to bone metastasis management, emphasizing early detection, proactive intervention, and the significant role of primary care providers in this process.

Explore the CML SUN study’s findings, which highlight the unmet need for shared decision-making in the choice of CML treatment—a void that may have an impact on patient satisfaction and treatment outcomes.

Dr. Susan Love, a revered figure in the realm of oncology, has left a legacy of patient advocacy and innovative research, driving physicians to approach patient care and cancer research with empathy, courage, and forward-thinking dynamism.

The phase 3 trial findings underscore the potential of axi-cel as a robust second-line treatment for early relapsed or refractory large B-cell lymphoma, providing promising strides in improving patient survival rates.